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ABSTRACT 
A series of 2-amino(chloro)-3-chloro-1,4-naphthoquinone derivatives (1-11) were investigated for their aromatase 
inhibitory activities. 1,4-Naphthoquinones 1 and 4 were found to be the most potent compounds affording IC50 
values 5.2 times lower than the reference drug, ketoconazole. A quantitative structure-activity relationship (QSAR) 
model provided good predictive performance (R2CV = 0.9783 and RMSECV = 0.0748) and indicated mass (Mor04m 
and H8m), electronegativity (Mor08e), van der Waals volume (G1v) and structural information content index 
(SIC2) descriptors as key descriptors governing the activity. To investigate the effects of structural modifications 
on aromatase inhibitory activity, the model was employed to predict the activities of an additional set of 39 struc-
turally modified compounds constructed in silico. The prediction suggested that the 2,3-disubstitution of 1,4-naph-
thoquinone ring with halogen atoms (i.e., Br, I and F) is the most effective modification for potent activity (1a, 1b 
and 1c). Importantly, compound 1b was predicted to be more potent than its parent compound 1 (11.90-fold) and 
the reference drug, letrozole (1.03-fold). The study suggests the 1,4-naphthoquinone derivatives as promising 
compounds to be further developed as a novel class of aromatase inhibitors.  
 
Keywords: 1,4-naphthoquinones, aromatase inhibitory activity, structural modification, computer-aided drug de-
sign, anticancer agents 
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INTRODUCTION 
The direct inhibition of estrogen synthesis 
targeting aromatase inhibition is considered 
to be an effective strategy towards breast can-
cer treatment (Altundag and Ibrahim, 2006; 
Brueggemeier et al., 2005; Favia et al., 2013). 
The majority of available non-steroidal aro-
matase inhibitors exhibit their competitive in-
hibitory activity through the coordination of 
the nitrogen (N) atom presented in the mole-
cule with the iron heme atom of the enzyme 
(Recanatini et al., 2002). Currently, aza-based 
aromatase inhibitors, i.e., letrozole and anas-
trozole, have been approved by the FDA as 
standard drugs for breast cancer treatment. In 
addition, natural products, i.e., flavonoids 
(Kao et al., 1998; Karjalainen et al., 2000; Le 
Bail et al., 2001) and sesquiterpene lactones 
(Blanco et al., 1997, 2001), whose carbonyl 
oxygen (O) atoms have been noted to play a 
role in heme coordination (Kao et al., 1998).   
1,4-Naphthoquinone scaffold is well 
known for its chelating ability and electro-
chemical properties (Hillard et al., 2008; 
Martinelli et al., 1999). It contains two ketone 
groups as crucial moieties, which are respon-
sible for many biological activities because of 
their abilities to accept electrons (Benites et 
al., 2010; O'Brien, 1991). Various biological 
activities of 1,4-naphthoquinone derivatives 
have been reported, i.e., anticancer (Kishore 
et al., 2014; Mallavadhani et al., 2014; Nasiri 
et al., 2013; Prachayasittikul et al., 2014b; 
Sreelatha et al., 2014), radical scavenging 
(Kumar et al., 2013; Lebedev et al., 2008; 
Song et al., 2000), antimicrobial (Ryu and 
Kim, 1992; Sreelatha et al., 2014; Tandon et 
al., 2009), antiviral (Crosby et al., 2011; Da 
Costa et al., 2013; Ilina et al., 2002), antifun-
gal (Castro et al., 2013; Pawar et al., 2014; 
Tandon et al., 2009), antitrypanocidal 
(Salmon-Chemin et al., 2001) and antiplatelet 
(Jin et al., 2004; Kuo et al., 2011; Lien et al., 
2002; Yuk et al., 2000) activities. It was found 
that structural modification can effectively 
modulate the electrochemical behavior of 1,4-
naphthoquinone compounds, thereby affect-
ing their biological activities (Hillard et al., 
2008). The introduction of amino and/or 
chloro moieties into the core structure of 1,4-
naphthoquinone was documented to improve 
the redox potential of the compounds (Benites 
et al., 2010; Salunke-Gawali et al., 2014).  
Computational approaches have been rec-
ognized as fundamental tools for facilitating 
drug design and development (Mandal et al., 
2009; van de Waterbeemd and Gifford, 2003). 
Quantitative structure-activity relationship 
(QSAR) has been extensively employed to fa-
cilitate lead optimization (Cherkasov et al., 
2014; Cramer, 2012). QSAR correlates the 
chemical structure of compounds with their 
biological activities (Nantasenamat et al., 
2009, 2010; Prachayasittikul et al., 2014b), 
which provides information about influential 
chemical features, crucial moieties and phar-
macokinetic properties (Hansch et al., 2004; 
Prachayasittikul et al., 2014b).  
To date, 1,4-naphthoquinone derivatives 
have not been reported as aromatase inhibi-
tors. Based on the heme coordination mecha-
nism, 2-amino-1,4-naphthoquinone com-
pounds are considered to be a potential novel 
class of aromatase inhibitors because of the 
presence of heme coordinating atoms, i.e., 
amino N and carbonyl O atoms in their mole-
cules. Recently, a series of 2-amino-3-chloro-
1,4-naphthoquinones was reported to possess 
anticancer activity by our research group 
(Prachayasittikul et al., 2014b). Herein, a set 
of eleven 2-amino(chloro)-3-chloro-1,4-
naphthoquinone compounds (1-11, Figure 1) 
were investigated for their aromatase inhibi-
tory activities, and the experimental activities 
of the compounds (1-11) were used for QSAR 
analysis. To elucidate the effects of structural 
modification on the core structure of 2,3-di-
substituted-1,4-naphthoquinone, an addi-
tional set of 39 structurally modified com-
pounds derived from compound series 1-11 
(Figure 2) were constructed in silico, and their 
aromatase inhibitory activities were predicted 
using the constructed QSAR model.  
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Figure 1: Chemical structures of 1,4-naphthoqui-
none derivatives (1-11) 
 
 
MATERIALS AND METHODS 
Compounds and reagents  
A series of 1,4-naphthoquinone deriva-
tives (1-11) were synthesized as by a previ-
ously described method (Prachayasittikul et 
al., 2014b). A recombinant human aromatase 
(CYP19) and O-benzyl fluorescein benzyl es-
ter (DBF) were supplied with the BD Gen-
testTM kit from BD Biosciences-Discovery 
Labware (Woburn, USA). Dimethyl sulfox-
ide (DMSO) was obtained from EMD Milli-
pore (Billerica, MA, USA).  
 
Aromatase inhibition assay 
The aromatase inhibitory activity of com-
pounds 1-11 was investigated by the method 
previously described by Stresser et al. 
(Stresser et al., 2000), with minor modifica-
tions (Prachayasittikul et al., 2014a). The as-
say was performed with a Gentest kit using 
enzyme CYP19 and DBF as a fluorometric 
substrate. DBF was dealkylated by aromatase 
and then hydrolyzed, yielding the fluorescein 
product. Briefly, 100 µL of cofactor contain-
ing 78.4 µL of 50 mM phosphate buffer (pH 
7.4), 20 µL of 20x NADPH-generating sys-
tem (26 mM NADP+, 66 mM glucose-6-phos-
phate and 66 mM MgCl2), and 1.6 µL of 
100 U/mL glucose-6-phosphate dehydrogen-
ase was pipetted into a 96-well plate and pre-
incubated in a water bath (37 °C) for 10 min. 
The reaction was initiated by adding 100 µL 
of an enzyme/substrate mixture containing 
77.3 µL of 50 mM phosphate buffer (pH 7.4), 
12.5 µL of 16 pmol/mL CYP19, 0.2 µL of 0.2 
mM DBF and 10 µL of tested compound or 
10 % DMSO as a negative control or ketocon-
azole/letrozole as a positive control. After the 
incubation at 37 °C for 30 min, the reaction 
was terminated by adding 50 µL of 2.2 N 
NaOH. The fluorescence signal was recorded 
using an excitation wavelength of 490 nm and 
an emission wavelength of 530 nm with a cut-
off of 515 nm. The percentage of inhibition 
(% inhibition) was calculated using Equation 
1. Compounds with greater than 50 % inhibi-
tion were determined to be active compounds 
and were further diluted and assayed in tripli-
cate. IC50 values were determined by plotting 
concentrations versus % inhibition. 
 
% inhibition = 100-[(sample-blank)/ 
                         (DMSO-blank) x 100] (1) 
 
QSAR analysis 
Conceptually, a QSAR model was con-
structed using the data obtained from experi-
mentally tested compounds (1-11). The con-
structed model was subsequently used to pre-
dict the activity of the additional set of struc-
turally modified compounds (series 1-11) that 
were generated in silico. The conceptual 
workflow of the QSAR study is shown in Fig-
ure 3. 
Data set 
Chemical structures of the tested com-
pounds (1-11) along with their experimental 
IC50 values were used to construct the QSAR 
model. The IC50 values were converted to 
pIC50 values by taking the negative logarithm 
to base 10 (-log IC50) to obtain a normal dis-
tribution of data points. Experimentally inac-
tive compounds were excluded from the data 
set.  
 
EXCLI Journal 2017;14:714-726 – ISSN 1611-2156 
Received: March 28, 2017, accepted: May 02, 2017, published: May 16, 2017 
 
 
717 
 
Figure 2: Chemical structures of structurally modified compounds (series 1-11) 
 
 
Figure 3: Workflow of the QSAR study 
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Geometry optimization and descriptor calcu-
lation 
The chemical structures of 11 tested com-
pounds (1-11) and 39 structurally modified 
compounds (series 1-11) were drawn using 
the GaussView software (Dennington et al., 
2003). Optimization was performed to obtain 
the low-energy conformers for further calcu-
lation of molecular descriptor values. The 
compounds were geometrically optimized us-
ing Gaussian 09 (Frisch et al., 2009) at the 
semi-empirical Austin Model 1 (AM1) level, 
followed by density functional theory (DFT) 
calculation using Becke’s three-parameter hy-
brid method with the Lee-Yang-Parr correla-
tion functional (B3LYP) together with the 6-
31g(d) level. A set of 13 quantum chemical 
descriptors, i.e., mean absolute atomic charge 
(Qm), total energy (Etotal), total dipole moment 
(μ), highest occupied molecular orbital energy 
(EHOMO), lowest unoccupied molecular orbital 
energy (ELUMO), energy difference of HOMO 
and LUMO (HOMO-LUMOGap), electron af-
finity (EA), ionization potential (IP), Mulli-
ken electronegativity (χ), hardness (η), soft-
ness (S), electrophilic index (ωi) and electro-
philicity (ω), was extracted using a script de-
veloped in-house. The optimized structures 
were further calculated to obtain an additional 
set of 3,224 molecular descriptors using 
Dragon software version 5.5 (Talete, 2007). 
The molecular descriptors obtained from the 
Dragon software included 22 classes, i.e., 
Constitutional descriptors, Topological de-
scriptors, Walk and path counts, Connectivity 
indices, Information indices, 2D autocorrela-
tion, Edge adjacency indices, Burden eigen-
values, Topological charge indices, Eigen-
value-based indices, Randic molecular pro-
files, Geometrical descriptors, RDF de-
scriptors, 3D-MoRSE descriptors, WHIM de-
scriptors, GETAWAY descriptors, Func-
tional group counts, Atom-centered frag-
ments, Charge descriptors, Molecular proper-
ties, 2D binary fingerprints and 2D frequency 
fingerprints. 
 
Feature selection 
Correlation-based feature selection was 
employed to initially select important de-
scriptors from a large set of descriptors ob-
tained from the calculation. The pair-correla-
tion of each descriptor value and bioactivity 
(pIC50) was calculated using a Pearson’s cor-
relation coefficient (r) of 0.6 as a cut-off 
value. Descriptors with |r| < 0.6 were consid-
ered weakly correlated descriptors and were 
excluded from the study, whereas those with 
|r| ≥ 0.6 were selected for further selection 
process using stepwise multiple linear regres-
sion (MLR) as implemented in SPSS statistics 
18.0 (SPSS Inc., USA). Finally, a set of im-
portant descriptors was obtained for multivar-
iate analysis.   
Multivariate analysis  
Multivariate analysis was performed by 
Waikato Environment for Knowledge Analy-
sis (WEKA) version 3.4.5 (Witten et al., 
2011) using a multiple linear regression 
(MLR) algorithm. Selected descriptor values 
and pIC50 values were assigned as independ-
ent variables (X) and dependent variables (Y), 
respectively. The MLR model was con-
structed according to Equation 2:  
 
 nnXBBY 0                (2) 
where Y represents the pIC50 values of the 
compounds, B0 is the intercept and Bn are the 
regression coefficients of descriptors Xn. 
Data sampling 
The data set was divided into a training set 
and a testing set by means of leave-one-out 
cross validation (LOO-CV). Conceptually, 
one sample was removed from the entire data 
set (N) and was used as the testing set, 
whereas the remaining samples (N-1) were 
used as the training set. The same sampling 
process was continued until every sample in 
the data set was used as the testing set to pre-
dict the variable Y (activity).  
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Evaluating the performance of QSAR model 
Two statistical parameters were used to 
assess the predictive performance of the con-
structed QSAR model. The squared correla-
tion coefficient (R2) represented the predic-
tive performance, and the root mean square 
error (RMSE) represented the predictive error 
of the model.  
Prediction of structurally modified  
compounds (series 1-11)  
All structurally modified compounds 
were drawn, optimized and calculated to ob-
tain a set of important descriptor values as de-
scribe above. The QSAR equation obtained 
from the QSAR analysis of tested compounds 
(1-11) was used to calculate the predicted ac-
tivity of the modified compound series. The 
descriptor values of modified compounds 
were replaced in the equation by independent 
variables (X) to predict their aromatase inhib-
itory activity (pIC50).  
 
RESULTS AND DISCUSSION 
Aromatase inhibitory activity  
The aromatase inhibitory activity of the 
quinone compounds (1-11) are summarized in 
Table 1. The compounds were categorized ac-
cording to their aromatase inhibitory activi-
ties (IC50) as highly active (IC50 < 1 µM), 
moderately active (1 µM < IC50 < 10 µM), 
weakly active (IC50 > 10 µM) and inactive (% 
inhibition ≤ 50 % at 12.5 µM) (Prachaya-
sittikul et al., 2014b). The results indicate that 
compounds 1 and 4 are the most potent com-
pounds, affording equivalent IC50 values of 
0.5 ± 0.3 and 0.5 ± 0.4 µM, respectively. Both 
compounds (1 and 4) exhibited more potent 
aromatase inhibitory activity than did the ref-
erence drug, ketoconazole, as indicated by 
their IC50 values, which were 5.2-fold lower 
than the value obtained for ketoconazole (IC50 
= 2.6 ± 0.7 µM). Compounds 3 and 11 were 
found to be inactive, and the rest of the tested 
compounds exhibited moderately active (2, 6, 
7, 8, 9 and 10) to weak (5) activities. The or-
der of aromatase inhibitory activity was as 
follows: 1 ≈ 4 > 8 > 6 > 10 > 9 > 7 > 2 > 5 >> 
3 and 11. A detailed discussion regarding the 
structure-activity relationships of the tested 
compounds is provided in Supplementary in-
formation. 
 
 
Table 1: Aromatase inhibitory activity (IC50) of 1,4-naphthoquinone derivatives (1-11) 
Compound IC50 (µM) MRC-5 (µM)a SI 
1 0.5 ± 0.3b 22.99 ± 0.42 45.98 
2 8.7 ± 0.9c non-cytotoxic ND 
3 Inactivee 16.39 ± 1.28 ND 
4 0.5 ± 0.4b 8.60 ± 0.77 17.20 
5 18.0 ± 4.0d 86.05 ± 3.04 4.78 
6 3.1 ± 0.1c 15.53 ± 0.75 5.01 
7 5.3 ± 4.1c 12.28 ± 1.08 2.32 
8 1.9 ± 0.4c 20.78 ± 0.68 10.94 
9 4.7 ± 0.5c 13.59 ± 1.33 2.89 
10 3.3 ± 1.9c non-cytotoxic ND 
11 Inactivee non-cytotoxic ND 
Ketoconazolef 2.6 ± 0.7 - h  
Letrozolef 0.33 ± 0.4g - h  
Doxorubicinf - h non-cytotoxic  
a Literature reported (Prachayasittikul et al., 2014b), b Highly active compound, c Moderately active com-
pound, d Weakly active compound,e Inactive denotes compound with ≤ 50 % inhibition at 12.5 µM, f 
Ketoconazole, letrozole and doxorubicin were used as reference drugs, g IC50 is determined as nM, -h = 
Not tested, ND = not determined, SI = selectivity index calculated by ratio of IC50 normal cell/IC50 aro-
matase inhibitory activity
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The cytotoxicity of compounds 1–11 
against the normal MRC-5 cell line (Table 1) 
was previously documented (Prachayasittikul 
et al., 2014b). Moderately active compounds 
2 and 10 and inactive compound 11 were 
shown to be non-cytotoxic. It should be noted 
that both of the highly active aromatase inhib-
itors (1 and 4) exhibited a high safety index 
with selectivity index values of 45.98 and 
17.20, respectively. However, compound 4 
displayed higher cytotoxicity than compound 
1.  
 
QSAR analysis of naphthoquinones 1 - 11 
A set of five informative descriptors (i.e., 
Mor04m, Mor08e, H8m, G1v and SIC2) was 
obtained using correlation-based feature se-
lection. Definitions of the selected descriptors 
and the descriptor values of the investigated 
compounds are presented in Table 2 and Sup-
plementary Table S1, respectively. The 
QSAR model (Equation 3) was successfully 
constructed using a multiple linear regression 
(MLR) algorithm.  
 
pIC50 = -0.4929(Mor04m) - 0.5018(Mor08e)  
- 7.9203(H8m) + 7.7183(G1v)  
- 1.0872(SIC2) - 0.2579                       (3) 
 
The model provided suitable predictive 
performance, affording R2Tr = 0.9984 and 
RMSETr = 0.0192 for the training set and R2CV 
= 0.9783 and RMSECV = 0.0748 for the test-
ing set. The experimental and predicted activ-
ities (pIC50 values) of the compounds (1 - 11) 
in the data set are summarized in Supplemen-
tary Table S2 and Figure 4.  
The QSAR analysis (Equation 3) revealed 
that the mass (Mor04m and H8m), electro-
negativity (Mor08e), van der Waals volume 
(G1v) and structural information content in-
dex (SIC2) descriptors are influential de-
scriptors governing the aromatase inhibitory 
activity of the compounds. The mass-
weighted descriptor H8m was found to be the 
most influential descriptor, as indicated by the 
highest regression coefficient of -7.9203. The 
negative regression coefficient indicated that 
the low value of H8m is required for potent 
activity. Similarly, low values are required for 
other important descriptors with negative re-
gression coefficients, i.e., Mor04m, Mor08e, 
and SIC2, whereas the high value of the de-
scriptor with a positive regression coefficient, 
i.e., G1v, is required for suitable activity. A 
comprehensive analysis of SAR was per-
formed to elucidate the effects of substituents 
on important descriptor values and aromatase 
inhibitory activity, the results of which are 
summarized in Supplementary Table S3.  
 
 
 
Table 2: Definition of descriptors used for development of QSAR models 
Descriptor Type Definition 
Mor04m 3D-MoRSE descriptors Signal 04 / weighted by mass 
Mor08e 3D-MoRSE descriptors Signal 08 / weighted by Sanderson electronegativity 
H8m GETAWAY descriptors H autocorrelation of lag 8 / weighted by mass 
G1v WHIM descriptors 1st component symmetry directional WHIM index / 
weighted by van der Waals volume 
SIC2 Information indices Structural information content index (neighborhood  
symmetry of 2-order) 
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Figure 4: Plot of experimental versus predicted 
pIC50 values of aromatase inhibitory activity of the 
tested compounds generated by the QSAR model 
(training set: compounds are represented by filled 
circles, and the regression line is shown as a solid 
line; leave-one-out validated testing set: com-
pounds are represented by open hexes, and the 
regression line is shown as a dotted line). 
 
 
Compound 1 (2,3-dichloro-1,4-naphtho-
quinone) was used as a prototype or a parent 
compound for comparison with its derivatives 
as 2-amino-3-chloro-1,4-naphthoquinones 
(2–11). It was found that compound 4 was the 
only one that exhibited experimental activity 
comparable to that of compound 1 (highly ac-
tive), whereas the rest of the compounds dis-
played lower potent activity (moderately to 
weakly active) (Table 1). The experimental 
results indicate that the replacement of the 2-
chloro group of 1 with amino phenyl ring 
leads to compound 3 with a loss of activity 
(Table S3, Panel 2). The deleterious effects 
may be due to an alteration of the mass, elec-
tronegativity and van der Waals volume of 
the compound, as indicated by the Mor04m, 
Mor08e and G1v values (Table S1 and Table 
S3, Panel 2). A remarkable reduction in G1v 
but increases in Mor04m and Mor08e were 
noted for the inactive compound 3 compared 
to the most potent compound 1, which 
showed lower Mor04m (1.226) and Mor08e  
(-0.928) values but higher G1v (0.193) values 
(Table S1). Such descriptor values are well 
correlated with the results of the QSAR 
model, as previously mentioned. However, 
improved activities were observed when var-
ious types of substituents were placed on the 
2-amino group (Table S3, Panel 3) or on the 
phenyl ring of the 2-amino group (Table S3, 
Panels 4 – 7). In particular, the highly potent 
activity of the compound 4 is governed by the 
additional substitution of the CH3 group on 
the 2-amino group of inactive compound 3, 
which causes the opposite effect on related 
descriptors (i.e., Mor04m, Mor08e and G1v) 
such that it enhances the activity (Table S3, 
Panel 3). Compound 4 showed a higher G1v 
value (0.190) but lower Mor04m (1.104) and 
Mor08e (-0.728) values compared with those 
of compound 3, which showed a lower G1v 
(0.619) value but higher Mor04m (1.672) and 
Mor08e (-0.494) values.  
In comparing N-phenyl compounds (5–8) 
with compound 4 (Table S1), it was found 
that compound 8 showed higher values of 
Mor04m (1.499), Mor08e (-0.478) and H8m 
(0.021) but a lower G1v value (0.169) than the 
most potent compound 4 (Mor04m = 1.104, 
Mor08e = -0.728, H8m = 0.002 and G1v = 
0.190). Similar effects were noted for com-
pounds 5–7, which showed higher Mor04m, 
Mor08e and H8m values but lower G1v val-
ues than compound 4. Such high values of 
mass (Mor04m and H8m) and electronegativ-
ity (Mor08e) descriptors could be due to the 
effects of substituents (R= NHPh, COCH3, 
and CO2H) on the Ph ring of secondary 
amines (5–8), and lower values of van der 
Waals volume were observed when compar-
ing with the tertiary amine 4. Among the com-
pounds 5–8, the one with an electron-donat-
ing group at the para-position (8, R = NHPh) 
had a lower Mor08e value (-0.478) compared 
to that with an electron-withdrawing group at 
the para-position (7, R = COCH3, Mor08e = 
-0.280). Compound 6, with R (COCH3) at the 
meta-position, showed a lower Mor08e value 
(-0.642) compared with its para-isomer (7). 
For the ortho-CO2H group (R) of compound 
5, a higher Mor08e value (-0.182) was ob-
served. The results suggest that the electronic 
effects of R groups provided a Mor08e value 
that is well correlated with the activity, in 
which a lower Mor08e value yielded a higher 
activity for the compounds, as noted for com-
pounds 8 > 6 > 7 > 5 (Table S1). 
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Likewise, the substitution of the 2-chloro 
group on the naphthoquinone ring by an 
amino alkyl chain can reduce the activity of 
the compound, as observed for compound 2 
(Table S3, Panel 1). The conversion of the N-
alkyl chain of compound 2 to an N-alkyl-
phenyl group afforded compound 10 with an 
increased G1v value but decreased Mor04m 
and Mor08e values that improved the activity 
of the compound. On the other hand, the in-
troduction of diOCH3 into the terminal phenyl 
ring of compound 10 yielded inactive com-
pound 11 with a decreased G1v value. Inter-
estingly, compound 10 (IC50 = 3.3 µM) exhib-
ited relatively high and comparable activity to 
that of compound 6 (IC50 = 3.1 µM). This 
finding could be attributed to the flexible 
ethyl phenyl group on the 2-amino position of 
compound 10 (low Mor08e or electron-donat-
ing effect but high G1v values) that causes the 
molecule to exist in a more favorable form 
when interacting with the target site. In con-
trast, the diOCH3 groups of compound 11 
might produce a bulky molecule that is unfa-
vorable for exerting the activity. N-anilinyl 
analog 9 (Table S3, Panel 8) showed a lower 
Mor08e value (-1.001) but a higher G1v value 
(0.179) than did N-phenyl analog 3 (Mor08e 
= -0.494, G1v = 0.169), thereby giving rise to 
more potent activity for the former.  
 
Prediction of structurally modified  
compounds (series 1-11) 
The predicted activities of all modified 
compounds are presented in Table S4. Simi-
larly to the tested compounds, the modified 
compounds were categorized according to 
their predicted activity (Prachayasittikul et 
al., 2014b). The majority of the modified 
compounds were predicted as moderately ac-
tive aromatase inhibitors. Some of the modi-
fied compounds (Table S4) exhibited more 
potent activity than the reference drug keto-
conazole but less than letrozole (i.e., 1a, 1c, 
2f, 3a, 4a, 4b, 4d, 4e, 4f, 5d, 6c, 7b, 7c, 8a, 
8b and 8c).  
The predictions showed that structural 
modifications can either improve or deterio-
rate the aromatase inhibitory activity of the 
compounds. 2,3-Disubstitution of the 1,4-
naphthoquinone ring with halogen atoms (i.e., 
Br, I and F) was found to be the most effective 
strategy, as indicated by the highly potent ac-
tivity of all modified compounds in series 1 
(Table S4). Importantly, compound 1b exhib-
ited the most potent activity among the tested 
and modified compounds, affording pIC50 
values 11.90-fold and 1.03-fold greater than 
those of the parent compound 1 (experimental 
pIC50 0.301, Table S2) and the reference drug 
letrozole (experimental pIC50 3.482, Table 
S4), respectively. Greatly improved activity 
was also observed in other compounds in the 
same series, such as compound 1c (predicted 
pIC50 0.614, Table S4). This compound was 
ranked as the second most potent aromatase 
inhibitor, in which the activity was improved 
2.04-fold compared to that of the parent com-
pound 1. Likewise, compound 1a (predicted 
pIC50 0.550, Table S4) was the third most po-
tent compound, with a 1.83-fold improvement 
in activity compared to that of parent com-
pound 1. The effects of structural modifica-
tions were elucidated by analyzing the rela-
tionship between descriptor values and activ-
ity, as summarized in Supplementary Table 
S5. It could be deduced that the markedly im-
proved activities of the modified compounds 
in series 1 may be governed by the substituted 
halogen atoms, which reduce the mass-
weighted descriptor (Mor04m) values of the 
compounds. In particular, the lowest Mor04m 
value (-5.734) was observed for the most po-
tent compound 1b, whereas the parent com-
pound 1 exhibited the highest Mor04m value 
(1.226), followed by compounds 1a (0.479) 
and 1c (0.465). It should be noted that the 
modified compounds (1a, 1b, 1c) and the par-
ent compound 1 showed the same values for 
the descriptors H8m, SIC2, and G1v (i.e., 0, 
0.707 and 0.193, respectively). However, 
these compounds showed different Mor08e 
values: 1b = -0.583, 1a = -0.644, 1c = -0.757 
and 1 = -0.928 (Table S1). 
Mono-substitution of the 2-chloro group 
in the core structure (compound 1) by amino-
based moieties produced 2-amino-3-chloro 
compounds with diverse effects. Compared 
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with the activity of compound 1, reduced ac-
tivities were observed in all modified com-
pounds in series 2-11, except for compound 
4a (predicted pIC50 0.326, Table S4), which 
exhibited more potent activity, as indicate by 
a pIC50 value that was 1.08-fold greater than 
that of the parent compound 1 but 10.68-fold 
less potent than the reference drug, letrozole.  
Results obtained from the modified com-
pounds in series 4 indicated that the length of 
the substituted alkyl chain (R1) and type of 
substituted ring (R2) on the amino group at the 
C-2 position of the 1,4-naphthoquinone core 
affected the aromatase inhibitory activity of 
the compounds via the alterations of mass 
(Mor04m and H8m), electronegativity 
(Mor08e) and van der Waals volume (G1v). 
Substitution with the phenyl group (R2) of 
compounds 4a (R1 = C2H5) and 4b (R1 = 
C3H7) and with the 1-adamantyl group (R2) of 
compounds 4e (R1 = CH3) and 4f (R1 = C2H5) 
on the amino moiety led to highly potent com-
pounds, whereas the compounds substituted 
with a cyclohexyl ring (R2), i.e., 4c (R1 = 
CH3) and 4d (R1 = C2H5), exhibited less po-
tent activity. Apparently, substitution with a 
2C (C2H5) alkyl chain (R1) in combination 
with a phenyl ring (R2) yielded a tertiary 
amine (4a), which was considered to be the 
most appropriate modification of 1,4-naph-
thoquinones with 2-substituted amino moie-
ties. Among the modified compounds in se-
ries 4, compound 4a showed the lowest H8m 
value (0.002) but a relatively high G1v value 
(0.162).  
The effects of ortho-/meta-/para-anilinyl 
(C6H6N) substituted onto the amino phenyl 
ring along with the presence of an additional 
methyl (CH3) substituent on the 2-amino 
group of the 1,4-naphthoquinone core were 
investigated in modified compound series 8. 
The para-aniline compound 8 (pIC50 -0.279) 
exerted more potent activity than did the 
meta-compound 8b (pIC50 -0.390), which 
could be due to the alteration of the mass de-
scriptor, H8m (8 = 0.021, 8b = 0.002, Table 
S1). Furthermore, remarkable enhancement 
effects were observed when the methyl group 
was introduced into the 2-amino position of 
both the para- (8a, pIC50 0.259) and meta- 
(8c, pIC50 0.123) aniline compounds, among 
which 8a was shown to be the most potent 
compound. The markedly increased activity 
of N-methyl-substituted compounds 8a and 
8c may be governed by the mass descriptor, 
as indicated by the 0.49-fold and 0.33-fold de-
creases in their Mor04m values compared 
with those of non-substituted N-methyl com-
pounds 8 and 8b, respectively. Likewise, the 
effects of ortho-/meta-/para-carboxyl 
(COOH) and acetyl (COCH3) substitutions on 
the amino phenyl ring were investigated in 
modified compound series 5, 6, and 7 (de-
tailed discussion is provided in Supplemen-
tary information). 
Similarly, the activity of modified com-
pound series 2, 3, 9, 10 and 11 were affected 
by other factors, i.e., the length of the alkyl 
chain, methyl substitution at the 2-amino 
group, diOMe substitution on the terminal 
phenyl ring, and type of substituted ring (de-
tailed discussion is provided in Supplemen-
tary information). 
Finally, the comprehensive SAR analysis 
of both tested and modified compounds re-
vealed that certain functional groups substi-
tuted in a particular position and/or in a dis-
tinct combination are essential for improving 
the aromatase inhibitory activity of the com-
pounds by altering important descriptor val-
ues governing the activity (Supplementary 
Table S4). 
 
CONCLUSION 
A series of 2,3-disubstituted-1,4-naphtho-
quinone derivatives (1-11) were investigated 
for their aromatase inhibitory activities. Com-
pounds 1 (2,3-dichloro) and 4 (2-amino-3-
chloro) exhibited the most potent activity, af-
fording IC50 values 5.2-fold lower than that of 
the reference drug, ketoconazole. The QSAR 
study revealed that mass (Mor04m and H8m), 
electronegativity (Mor08e), van der Waals 
volume (G1v) and structural information con-
tent index (SIC2) descriptors are influential 
descriptors governing aromatase inhibitory 
activity. The 2,3-dihalogen derivatives (1a, 
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1b and 1c) were predicted to be the most po-
tent modified series, affording predicted pIC50 
values in range of 0.550 - 3.582. The predic-
tion suggested that considerably improved ac-
tivity can be achieved when the 2,3-position 
of the 1,4-naphthoquinone rings are substi-
tuted by halogen atoms with high lipophilicity 
and electronegativity (i.e., Br, I and F). Nota-
bly, the 2,3-diiodo compound 1b exhibited 
the most potent predicted activity affording 
the pIC50 value 11.90-fold and 1.03-fold 
greater than those of its parent compound 1 
and the reference drug (letrozole), respec-
tively. Finally, this study provides pertinent 
knowledge regarding drug design and devel-
opment and suggests that 1,4-naphthoqui-
none-based compounds can be further devel-
oped as a novel class of aromatase inhibitors.  
 
Supplementary information 
Supplementary information is available 
on the EXCLI Journal website. 
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